Go Pro
NASDAQ:VBIO

Valion Bio, Inc. Common Stock (VBIO) Stock Price, News & Analysis

Valion Bio, Inc. Common Stock logo
$0.31 +0.02 (+7.64%)
As of 04:00 PM Eastern

About Valion Bio, Inc. Common Stock Stock (NASDAQ:VBIO)

Advanced

Key Stats

Today's Range
$0.28
$0.36
50-Day Range
$0.27
$0.80
52-Week Range
$0.25
$5.60
Volume
1.34 million shs
Average Volume
375,294 shs
Market Capitalization
$1.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use. ClearUP employs a small, ergonomic applicator that is applied externally to designated points on the face for brief treatment sessions. Tivic Health has conducted clinical studies demonstrating significant reductions in sinus pain and congestion, and the device is rechargeable and portable to facilitate daily self-care routines.

Headquartered in northern California, Tivic Health Systems sells ClearUP directly to consumers via its e-commerce platform and through select retail and healthcare distribution partners. The company continues to expand its commercial footprint by forging alliances with pharmacies, online retailers and professional allergy and sinus care networks. While its initial focus has been the U.S. market, Tivic Health is evaluating opportunities for international expansion and additional product indications.

Founded in 2013, Tivic Health completed its initial public offering in October 2020 and is listed on the NASDAQ under the symbol TIVC. The company is led by a management team with deep experience in medical device development, clinical research and healthcare commercialization, all focused on bringing non-invasive therapeutic innovations to patients suffering from chronic sinus and nasal disorders.

AI Generated. May Contain Errors.

Valion Bio, Inc. Common Stock Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

VBIO MarketRank™: 

Valion Bio, Inc. Common Stock scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Valion Bio, Inc. Common Stock has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Valion Bio, Inc. Common Stock has only been the subject of 1 research reports in the past 90 days.

  • Read more about Valion Bio, Inc. Common Stock's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Valion Bio, Inc. Common Stock is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Valion Bio, Inc. Common Stock is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Valion Bio, Inc. Common Stock has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Valion Bio, Inc. Common Stock's valuation and earnings.
  • Percentage of Shares Shorted

    6.50% of the float of Valion Bio, Inc. Common Stock has been sold short.
  • Short Interest Ratio / Days to Cover

    Valion Bio, Inc. Common Stock has a short interest ratio ("days to cover") of 1.31, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Valion Bio, Inc. Common Stock has recently increased by 69.99%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Valion Bio, Inc. Common Stock does not currently pay a dividend.

  • Dividend Growth

    Valion Bio, Inc. Common Stock does not have a long track record of dividend growth.

  • Search Interest

    1 people have searched for VBIO on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Valion Bio, Inc. Common Stock to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Valion Bio, Inc. Common Stock insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.50% of the stock of Valion Bio, Inc. Common Stock is held by insiders.

  • Percentage Held by Institutions

    4.25% of the stock of Valion Bio, Inc. Common Stock is held by institutions.

  • Read more about Valion Bio, Inc. Common Stock's insider trading history.
Receive VBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valion Bio, Inc. Common Stock and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VBIO Stock News Headlines

Valion Bio, Inc.
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
See More Headlines

VBIO Stock Analysis - Frequently Asked Questions

Valion Bio, Inc. Common Stock's stock was trading at $1.45 on January 1st, 2026. Since then, VBIO shares have decreased by 78.3% and is now trading at $0.3140.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($2.23) earnings per share (EPS) for the quarter.
Read the conference call transcript
.

Valion Bio, Inc. Common Stock shares reverse split before market open on Wednesday, August 23rd 2023.The 1-100 reverse split was announced on Wednesday, August 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Top institutional investors of Valion Bio, Inc. Common Stock include Foster & Motley Inc. (1.29%) and HS Management Partners LLC (0.99%). Insiders that own company stock include Christina Rizopoulos Valauri and Sheryle Bolton.
View institutional ownership trends
.

Shares of VBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Valion Bio, Inc. Common Stock investors own include Meta Platforms (META), CrowdStrike (CRWD), Applied DNA Sciences (APDN), Bionomics (BNOX), Cameco (CCJ) and BlackRock ESG Capital Allocation Term Trust (ECAT).

Company Calendar

Last Earnings
5/14/2026
Today
8/11/2026
EGM 2026
8/14/2026
Next Earnings (Estimated)
8/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VBIO
Previous Symbol
NASDAQ:TIVC
CIK
1787740
Fax
N/A
Employees
10
Year Founded
2016

Profitability

EPS (Trailing Twelve Months)
($6.68)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.88 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-138.10%
Return on Assets
-63.67%

Debt

Debt-to-Equity Ratio
0.62
Current Ratio
3.31
Quick Ratio
3.02

Sales & Book Value

Annual Sales
$780 thousand
Price / Sales
1.65
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.65 per share
Price / Book
0.05

Miscellaneous

Outstanding Shares
4,150,000
Free Float
4,047,000
Market Cap
$1.29 million
Optionable
Not Optionable
Beta
1.85

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:VBIO) was last updated on 8/11/2026 by MarketBeat.com Staff.
From Our Partners